Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2019—Biodesix (Boulder, Colo.) announced that it will acquire Oncimmune’s U.S. operations, which include a CLIA lab in De Soto, Kan., and the company’s incidental pulmonary nodule malignancy test, Early-CDT Lung.
October 2019—The U.S. Federal Bureau of Investigation has approved Thermo Fisher Scientific’s Applied Biosystems Precision ID System mtDNA analysis solution for use by forensic laboratories to generate mitochondrial DNA profiles for submission to the U.S. National DNA Index System CODIS database.
October 2019—Helmer Scientific launched its upright laboratory, pharmacy, and blood bank GX Solutions refrigerators, with models ranging from 13 to 56 cubic feet. GX Solutions are designed to keep temperatures within ±1°C throughout the unit, recover quickly from temperature changes after prolonged door openings, and maintain temperature stability.
October 2019—Menarini Silicon Biosystems launched its VRNxT, a sample preparation instrument that automates volume reduction steps in rare cell analysis workflows.
October 2019—ARUP Laboratories and Techcyte, a developer of artificial intelligence–based image analysis solutions for the diagnostics industry, have developed an AI-augmented ova and parasite detection tool.
October 2019—The FDA approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first noninsulin drug approved to treat type 2 diabetes in pediatric patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.
October 2019—Bio-Rad Laboratories received FDA 510(k) clearance for its IH-500, an automated random access system for blood typing and screening, designed for small to medium-size laboratories. The system can process Bio-Rad’s range of IH gel cards for ABO blood grouping, reverse testing, phenotyping, Rh subgroups, antibody screening, antibody identification, single antigen testing, direct AHG testing, and crossmatching. In a separate release, the company announced FDA clearance for its BioPlex 2200 Lyme Total Assay, a multiplex test method to aid in
September 2019—Clever Culture Systems announced FDA 510(k) clearance of its APAS Independence instrument and associated urine analysis module as a class II medical device. The APAS Independence automatically screens, interprets, and sorts culture plates and can process more than 200 culture plates at a time. The instrument sorts culture plates showing significant bacterial growth from those that do not, without the need for further microbiologist assistance, the company says.
September 2019—The U.S. Food and Drug Administration permitted marketing of the Synovasure Lateral Flow Test Kit (CD Diagnostics) as an aid for the detection of periprosthetic joint infection in the synovial fluid of patients being evaluated for revision surgery. The test kit detects human alpha defensins in the synovial fluid of patients with a total joint replacement in approximately 10 minutes. The test is not intended to identify a specific type of infection.
September 2019—Mesa Biotech launched its respiratory syncytial virus test, the company’s second point-of-care test on its polymerase chain reaction testing platform, the Accula System, at the AACC annual scientific meeting. The Accula Flu A/Flu B test received FDA clearance in 2018. Both tests are indicated for use with nasal swab collection.
